142 related articles for article (PubMed ID: 21256572)
1. Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
Alan C; Kırılmaz B; Koçoğlu H; Ersay AR; Ertung Y; Eren AE
Urology; 2011 Jun; 77(6):1439-43. PubMed ID: 21256572
[TBL] [Abstract][Full Text] [Related]
2. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of apoptosis indexes in currently used oral alpha-blockers in prostate: a pilot study.
Demir M; Akin Y; Terim KAK; Gulum M; Buyukfirat E; Ciftci H; Yeni E
Int Braz J Urol; 2018; 44(3):600-607. PubMed ID: 29617082
[TBL] [Abstract][Full Text] [Related]
4. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Kyprianou N; Chon J; Benning CM
Prostate Suppl; 2000; 9():42-6. PubMed ID: 11056502
[TBL] [Abstract][Full Text] [Related]
5. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Keledjian K; Kyprianou N
J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
[TBL] [Abstract][Full Text] [Related]
6. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
[TBL] [Abstract][Full Text] [Related]
9. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N
Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417
[TBL] [Abstract][Full Text] [Related]
10. [Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].
Larosa M; Ferretti S; Salsi P; Simonazzi M
Acta Biomed Ateneo Parmense; 1994; 65(1-2):23-8. PubMed ID: 7528458
[TBL] [Abstract][Full Text] [Related]
11. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Kyprianou N; Benning CM
Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
[TBL] [Abstract][Full Text] [Related]
12. Comparison of relaxation responses of cavernous and trigonal smooth muscles from rabbits by alpha1-adrenoceptor antagonists; prazosin, terazosin, doxazosin, and tamsulosin.
Seo KK; Lee MY; Lim SW; Kim SC
J Korean Med Sci; 1999 Feb; 14(1):69-74. PubMed ID: 10102527
[TBL] [Abstract][Full Text] [Related]
13. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
14. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
Samli MM; Dincel C
Urol Int; 2004; 73(2):125-9. PubMed ID: 15331896
[TBL] [Abstract][Full Text] [Related]
15. [Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
Bar-Yosef Y; Mabjeesh NJ; Laufer M; Neulander EZ; Kaver I; Matzkin H
Harefuah; 2008 Jun; 147(6):514-9, 574. PubMed ID: 18693628
[TBL] [Abstract][Full Text] [Related]
16. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
17. Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs.
Brune ME; Katwala SP; Milicic I; Buckner SA; Ireland LM; Kerwin JF; Hancock AA
Pharmacology; 1996 Dec; 53(6):356-68. PubMed ID: 9032800
[TBL] [Abstract][Full Text] [Related]
18. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Elterman DS; Lawrentschuk N; Guns E; Hersey K; Adomat H; Wood CA; Fleshner N
J Urol; 2010 May; 183(5):2085-9. PubMed ID: 20303529
[TBL] [Abstract][Full Text] [Related]
19. Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume.
Paick JS; Cho MC; Song SH; Kim SW; Ku JH
J Korean Med Sci; 2008 Jun; 23(3):509-13. PubMed ID: 18583890
[TBL] [Abstract][Full Text] [Related]
20. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
